Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
September 16, 2022 16:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed
September 16, 2022 10:37 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced an educational campaign to inspire prostate cancer patients to speak up and seek support through...
Myovant Sciences to Participate at Upcoming Investor Conferences
September 02, 2022 06:45 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
August 16, 2022 16:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
August 05, 2022 20:50 ET
|
Myovant Sciences, Inc.
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less...
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
July 27, 2022 16:05 ET
|
Myovant Sciences, Inc.
First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
July 18, 2022 16:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, July 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
July 13, 2022 06:45 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for...
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
June 17, 2022 06:45 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies...
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
June 16, 2022 16:35 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science,...